These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 4679645)

  • 1. Antilipemic drugs and the position of the FDA.
    Finkel MJ
    Adv Exp Med Biol; 1972; 26(0):263-5. PubMed ID: 4679645
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: The UGDP scandal and cover-up.
    Moss JM
    JAMA; 1975 May; 232(8):806-8. PubMed ID: 1173182
    [No Abstract]   [Full Text] [Related]  

  • 3. The challenge of regulating development and approval of drugs with pleiotropic action in cardiovascular disease.
    Temple R
    Am J Cardiol; 1998 Apr; 81(8A):5F-9F. PubMed ID: 9604896
    [No Abstract]   [Full Text] [Related]  

  • 4. What kinds of studies should be required to probe efficacy and safety of drugs in special populations?
    LaRosa JC; Sneider GB; Boyle C
    Am J Cardiol; 1998 Apr; 81(8A):84F-87F. PubMed ID: 9604921
    [No Abstract]   [Full Text] [Related]  

  • 5. The FDA and hypoglycemic drugs.
    Davidson JK
    JAMA; 1975 May; 232(8):853-5. PubMed ID: 1091764
    [No Abstract]   [Full Text] [Related]  

  • 6. The oral hypoglycemic controversy. Stay as sweet as you are.
    Gregory DR
    Leg Aspects Med Pract; 1979 Mar; 7(3):16-9. PubMed ID: 106193
    [No Abstract]   [Full Text] [Related]  

  • 7. Tolbutamide study raises blood pressures.
    Nature; 1970 Dec; 228(5278):1251-2. PubMed ID: 5536884
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of the central clinical laboratory in the development of drugs for the treatment of cardiovascular disease by the modification of lipoprotein concentrations.
    Cole TG
    Am J Cardiol; 1998 Apr; 81(8A):75F-77F. PubMed ID: 9604917
    [No Abstract]   [Full Text] [Related]  

  • 9. Regulatory concerns at various phases of drug development.
    Aurecchia S; Orloff D; Sobel S
    Am J Cardiol; 1998 Apr; 81(8A):2F-4F. PubMed ID: 9604895
    [No Abstract]   [Full Text] [Related]  

  • 10. Editorial: Let's stop the Donnybrook. A perspective on the UGDP-Biometric Society Study.
    Moser RH
    JAMA; 1975 Mar; 231(12):1274-6. PubMed ID: 1172958
    [No Abstract]   [Full Text] [Related]  

  • 11. Potentiation of hypoglycemic effect of chlorpropamide and phenfromin by halofenate.
    Kudzma DJ; Friedberg SJ
    Diabetes; 1977 Apr; 26(4):291-5. PubMed ID: 321288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical watergate? Critics charge a cover-up at HEW of faulty research.
    Born RC
    Barrons; 1978 Oct; 58(43):9-10, 17-8. PubMed ID: 10238964
    [No Abstract]   [Full Text] [Related]  

  • 13. Tolbutamide: more questions than answers.
    Barclay WR
    JAMA; 1971 Jan; 215(1):108-9. PubMed ID: 5107341
    [No Abstract]   [Full Text] [Related]  

  • 14. Status of problem of usage of tolbutamide. Preliminary statements.
    Diabetes; 1970 Jun; 19(6):467-8. PubMed ID: 5467867
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA considerations regarding new hypolipidemic agents.
    Finkel MJ
    Lipids; 1977 Jan; 12(1):64-5. PubMed ID: 834124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of tolbutamide in diabetes and pregnancy].
    Villanueva Gasca A; María García L; López Villegas J; Núñez E
    Ginecol Obstet Mex; 1975 Aug; 38(226):133-7. PubMed ID: 1175987
    [No Abstract]   [Full Text] [Related]  

  • 17. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP).
    Seltzer HS
    Diabetes; 1972 Sep; 21(9):976-9. PubMed ID: 5055722
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial: Oral hypoglycemic drugs.
    Scoville AB
    J Tenn Med Assoc; 1975 Apr; 68(4):319-20. PubMed ID: 1117723
    [No Abstract]   [Full Text] [Related]  

  • 19. Tolbutamide: another view.
    Nahum LH
    Conn Med; 1971 Apr; 35(4):272-3. PubMed ID: 5108037
    [No Abstract]   [Full Text] [Related]  

  • 20. Controlled clinical trials and the tolbutamide controversy.
    Lavietes PH
    Conn Med; 1971 Apr; 35(4):271-2. PubMed ID: 4927818
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.